anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Helicobacter pylori, previously known as Campylobacter pylori, is a gram-negative, microaerophilic bacterium usually found in the stomach. It was identified in 1982 by Australian scientists Barry Marshall and Robin Warren, who found that it was present in a person with chronic gastritis, gastric ulcers and conditions not previously believed to have a microbial cause. It is also linked to the development of duodenal ulcers and stomach cancer. However, over 80% of individuals infected with the bacterium are asymptomatic, and it may play an important role in the natural stomach ecology. \[1\] More than 50% of the world's population have H. pylori in their upper gastrointestinal tract. \[2\] Infection is more common in developing countries than Western countries. \[3\] H. pylori's helical shape (from which the genus name derives) is thought to have evolved to penetrate the mucoid lining of the stomach. \[4, 5\] Microalbuminuria, which is defined as an increased urinary albumin to creatinine ratio (UACR) of 30-300 μg/mg .\[15\] Has been known to be a strong predictor of the development of diabetic nephropathy. \[16\] It has also been demonstrated that microalbuminuria is a risk factor for cardiovascular disease in the general and diabetic populations. \[17-19\] and the increased urinary leakage of albumin reflects vascular damage, i.e., endothelial dysfunction or low grade chronic inﬂammation. \[20\] In addition, some studies have reported a relationship between microalbuminuria and metabolic syndrome, suggesting that insulin resistance underlies the pathogenesis of microalbuminuria. \[21-23\]
The present application provides an artificial tissue or organ encapsulation apparatus, and a preparation method therefor and an application thereof. The encapsulation apparatus is arranged at the periphery of an artificial tissue or organ; the encapsulation efficiency of the encapsulation apparatus for the artificial tissue or organ is 20%-100%; the encapsulation apparatus has a hardness of 100 Pa-1 GPa. In an in vitro stage, the encapsulation apparatus provides the effects of protection, support, on-demand combination, assembly, function maintenance, etc. for an artificial tissue or organ, can achieve safe, accurate, and large-scale operations, such as culture and transport, construction, and culture and exchange, for the artificial tissue or organ, and further achieves applications in biological development research, high-throughput drug detection, atmosphere/environment/water body detection, etc.; in an in vivo stage, the encapsulation apparatus provides the effects of transplant transfer, positioning and fixation, suturing, structural protection, nutrition metabolism maintenance, etc. in transplant surgery for the artificial tissue or organ, and further enhances the effects of in vivo survival, vascularization, tissue formation, reconstruction, etc. of the transplanted tissue or organ.
After an exercise bout, angiogenesis is incredibly important in the recovery process as an increased number of capillaries enables higher metabolite transport to and from the working muscle. Often, a training strategy consists of living-high (sleeping at -stimulated- altitude) and training low (training at sea level). A decreased oxygen availability, also known as hypoxia, however poses an additional stress on the human body, potentially compromising the overall training efficiency. Ketones are recently found to increase angiogenesis in response to overload training (increased skeletal muscle capillarization and VEGF content) and to increase serum EPO concentrations. Therefore, the investigators want to evaluate the isolated and interactive effects of both ketones and hypoxia on post-exercise recovery and factors implicated in skeletal muscle angiogenesis, after training in normoxia. Moreover, a performance test will be performed after 7h of hypoxic or normoxic recovery by means of a simulated 15 min all-out time trial. During the 7h post-exercise window, biological samples are collected (muscle biopsies, venous blood samples, urine, capillary blood samples). Moreover, blood and muscle oxygenation, peripheral blood flow and cognitive function are assessed at regular timepoints.
The use of metoclopramide tablets is recommended for adults only. Therapy should not exceed 12 weeks in duration.

Symptomatic Gastroesophageal Reflux

Metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy.

The principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12 week trial using doses of 15 mg q.i.d. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically.

Diabetic Gastroparesis (Diabetic Gastric Stasis)

Metoclopramide tablets are indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three-week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more
Volitinib is a potent and selective small molecule c-Met kinase inhibitor. Volitinib was found to inhibit c-Met kinase at the enzyme and cell levels with IC50s of 4 nM for both enzyme and Met phosphorylation in the cell. Consistent with its potent enzyme and cell activity, volitinib was found to inhibit cell growth in vitro against tumors with c-Met gene amplification in the absence of HGF stimulation with IC50s generally below 10 nM. It also potently inhibited HGF-stimulated cell proliferation against tumors with c-Met overexpression or carrying a HGF/c-Met autocrine loop.

In a xenograft model Hs746T with c-Met gene amplification, suboptimal doses 0.6 mg/kg volitinib and 3 mg/kg docetaxel induced TGI(expand) of 55.8% and 80.8%, respectively, whereas combination resulted in a TGI by 101.1%, and statistical significance was seen between combination group and either of mono-therapy group. Plasma exposures of volitinib and docetaxel were determined after last dose at the end of study, and there was no significant difference between combination and single agent on exposures of either volitinib or docetaxel. More importantly, combination was well tolerant and no body weight loss was found in the animals. These results suggested that it would be worthwhile to study the combination use of volitinib and docetaxel in clinic.
FIELD: medicine. ^ SUBSTANCE: anti-cancer remedy obtaining method is based on coordination compound of bivalent platinum and in accordance with which the water solution containing humic substances is processed with the above platinum compound. As coordination platinum compounds, the compound of the following row is chosen: potassium tetrachloroplatinate, cis-dichlorodiamine platinum, hydrogen tetrachloroplatinate, potassium tetrabromoplatinate. Processing is performed under influence of wave radiation up to the value of content of high-molecular fraction of humic substances of not more than 5%. As wave radiation, there chosen is radiation in ultrasonic range of frequencies of 18 kHz to 66 kHz with power of 0.5 to 5 W/cm3. When radiation power is 5 W/cm3 and frequency is 22 kHz, processing is performed during 5-20 min. As wave radiation, there can be chosen radiation in microwave range of frequencies of 30 to 0.3 GHz and power of 0.5 to 50 W/cm3. When microwave radiation power is 0.5 W/cm3 and frequency is 2.45 GHz, the temperature of the processed product is maintained within 40-50C during 30-90 min. ^ EFFECT: method provides obtaining more than one homogeneous product which is more stable during storage by decreasing relative content of high-molecular fraction. ^ 6 cl, 5 ex, 5 tbl, 2 dwg
PURPOSE:To obtain platelet coagulation inhibitor effective for prevention and remedy of thrombosis having strong platelet coagulation-inhibiting activity containing acetylapoaranotin as active ingredient. CONSTITUTION:Acetylapoaranotin expressed by the formula is contained in the aimed inhibitor as active ingredient. The compound expressed by the formula is obtained using, e.g. Aspergillus terreus GSL 299 strain having excellent productivity among strains separated from soil. Said inhibitor is able to be used in both methods of oral and parenteral and suitable administration doses are respectively 0.5-20mg/kg for oral and 0.05-2mg/kg for parenteral administration. Formulation of tablet, powder, capsules, granule and suppository shapes are able to be used.
Instruct patients to do the following:

  * Take risedronate sodium tablets at least 30 minutes before the first food or drink of the day other than water, and before taking any oral medication or supplementation, including calcium, antacids, or vitamins to maximize absorption and clinical benefit, [see Drug Interactions (7.1)]. Avoid the use of water with supplements, including mineral water, because they may have a higher concentration of calcium.
  * Swallow risedronate sodium tablets whole with a full glass of plain water (6 to 8 ounces). Avoid lying down for 30 minutes after taking the medication [see Warnings and Precautions (5.1)]. Do not chew or suck the tablet because of a potential for oropharyngeal ulceration.
  * Do not eat or drink anything except plain water, or take other medications for at least 30 minutes after taking risedronate sodium tablets.
Bladder biopsies will be obtained during cystoscopy, conserved in culture medium (DMEM®), digested by dispase and sowed on collagen-coated culture support. Keratinocyte Serum Free Medium (KSFM) will be used for proliferation. Microscopy, immunohistochemistry, RNA extraction, Reverse Transcription and quantitative Polymerase Chain Reaction (RT-qPCR) will be performed during passages. Cell culture conditions will be optimized to improve proliferation and avoid loss of differentiation. The investigators will develop scaffolds based on sodium alginate hydrogels, followed by freeze-drying to generate porous sponges (at -20°C and -80°C). Cultured cells will be associated to these original scaffolds and to other scaffolds, for example alginate hydrogels or Collagen Cell Carrier (CCC), cultivated for 28 days and analyzed. Histological and immunohistological appearance of cellularized scaffolds will be compared to assess the effectiveness of each scaffold for tissue engineering in urothelium.

Cellularized scaffolds will be studied in vitro (Transepithelial Electrical Resistance, impermeability, ability to be stitched, resistance to urine) and in vivo in ectopic location (subcutaneous location in Nude mice) or in orthotopic location (bladder augmentation in small animal).
The invention belongs to the field of food processing, and particularly relates to a rutin chitosan oligosaccharide compound, and a preparation method and application thereof. Comprises rutin and chitosan oligosaccharide. The molar ratio of the rutin to the chitosan oligosaccharide is 1: 1-5. The invention provides a method for improving rutin bacteriostasis and oxidation resistance, improving rutin water solubility and reducing rutin bitter by utilizing chitosan oligosaccharide. The antibacterial activity and the antioxidant capacity of the tested compound are both obviously improved, the water solubility is obviously improved, the bitter taste is obviously reduced, and the result shows good feasibility and repeatability. The method provides a new idea for the innovative application of rutin in the fields of functional foods, medicines, cosmetics and the like.
Cohort #1: Patients undergoing simultaneous bilateral carpal tunnel release for treatment of bilateral carpal tunnel syndrome. Inclusion criteria includes any adult patient indicated for bilateral carpal tunnel release. Exclusion criteria include age less than 18, pregnancy, any protected patient population, and the lack of assistance at home during the early postoperative period.
PURPOSE:To provide the titled composition obtained by adding an aluminosilicate containing adsorbed carbon dioxide gas to a dentifrice compounded with various preventives and remedies for periodontosis, etc., capable of promoting the absorption of the above preventive and remedy or perfumery component through the oral mucosa by the action of generated carbon dioxide gas and giving refreshing feeling to the mouth. CONSTITUTION:A dentifrice containing various preventive and remedy for periodontosis, perfumery, etc., e.g. drugs such as ascorbic acid, fluorine compound, enzyme, etc., a surfactant, an abrasive, etc., is further compounded with an aluminosilicate containing adsorbed carbon dioxide gas as an active component. The aluminosilicate is preferably a synthetic zeolite of formula (M is metallic atom having atomic valence of n; x is 0.7-1.5; y is 0.8-10; z>=0) because of low impurity content. The metal is preferably calcium from the viewpoint of stability and that free of water is preferable. The particle diameter is preferably 0.5-100mu and especially 1-40mu to attain an excellent feeling to the mouth.
Pulsed electromagnetic field (PEMF) therapy is a potential non-invasive treatment to modulate immune responses and inhibit tumor growth. Cervical cancer (CC) is influenced by IL-37-mediated immune regulation, making PEMF therapy a potential strategy to impede CC progression. This study aimed to elucidate the effects of PEMF on IL-37 regulation and its molecular mechanisms in CC. CC cell-xenografted mouse models, including IL-37 transgenic (IL-37tg) mice, were used to assess tumor growth through in vivo fluorescence imaging and analyze CC cell apoptosis via flow cytometry. TCGA-CESC transcriptome and clinical data were analyzed to identify key inflammation and immune-related genes. CD8+ T cell models were stimulated with PEMF, and apoptosis, oxidative stress, and inflammatory factor expression were analyzed through RT-qPCR, Western blot, and flow cytometry. PEMF treatment significantly inhibited IL-37 expression (p < 0.05), promoted inflammatory factor release (TNF-α and IL-6), and activated oxidative stress, leading to increased CC cell apoptosis (p < 0.05). IL-37 interaction with SMAD3 impacted the p38/NF-κB signaling pathway, modulating CD8+ T cell activity and cytotoxicity. Co-culture of Hela cells with CD8+ T cells under PEMF treatment showed reduced proliferation (by 40%), migration, and invasion (p < 0.05). In vivo experiments with CC-bearing mice demonstrated that PEMF treatment downregulated IL-37 expression (p < 0.05), enhanced CD8+ T cell function, and inhibited tumor growth (p < 0.05). These molecular mechanisms were validated through RT-qPCR, Western blot, and immunohistochemistry. Thus, PEMF therapy inhibits CC progression by downregulating IL-37 and improving CD8+ T cell function via the SMAD3/p38/NF-κB signaling pathway.
AIM: The association of overweight/obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) in young adulthood with subclinical atherosclerosis [coronary artery calcification (CAC) and abdominal aortic calcification (AAC)] by middle age is unknown.
METHOD: In total, 2274 participants aged 28-39 years from the coronary artery risk development in young adults study at year 10 (1995-1996) who were re-examined 15 years later were included. CAC and AAC were measured at year 25 using computed tomography. We examined the utility of three young adult phenotypes (lean group; overweight/obese group; overweight/obese MASLD group) at year 10 in predicting CAC or AAC by middle age. Modified Poisson regression was used to estimate the association between groups and CAC, and AAC. Independent determinates of CAC and AAC were determined with linear regression models.
RESULTS: Compared with individuals categorized as lean in young adulthood, the relative risk for CAC by middle age was 1.09 (95% confidence interval: 0.93-1.28) for those with overweight/obesity and 1.32 (95% confidence interval: 1.08-1.61) for those with overweight/obesity-related MASLD. For AAC, no difference was observed between these three groups. Group, systolic blood pressure and group × systolic blood pressure interaction were all the independent determinates for CAC.
CONCLUSION: In this study, young adults with overweight/obesity-related MASLD have a higher risk of developing CAC by middle age. These abnormalities are only partially explained by traditional cardiovascular risk factors, and overweight/obesity-related MASLD has an independent impact on CAC. Our study provides evidence for identifying young adults at higher risk of developing subclinical atherosclerosis.
The present invention relates to hydroxyl camptothecin solid dispersion substances which comprise 1 weight portion of hydroxyl camptothecin and 8 to 80 weight portions of carriers, wherein the carriers are selected from any one kind of or two kinds of or all kinds of polyethyleneglycol 4000, polyethyleneglycol 6000, polyvinylpyrrolidone and poloxamer. 0.001 to 10 portions of surface active agent can be added to the solid dispersion substances. A preparation method for the hydroxyl camptothecin solid dispersion substances comprises: hydroxyl camptothecin is pulverized into powder with the diameters of 0.1 to 400 micrometers, and the powder is added to the molten carriers to be sufficiently stirred and suspended; the powder is then rapidly cooled, and a cooling temperature is from-273 to 15 DEG C; the powder is then dried and solidified, and the hydroxyl camptothecin solid dispersion substances are formed. Hydroxyl camptothecin can be made into an oral-administration preparation with good dissolution by the present invention, and moreover, an oral-administration mode is more convenient for operation. The hydroxyl camptothecin solid dispersion substances of the present invention are more suitable for the clinical application of chemotherapeutic medicine of camptothecin with long-term medication. The dissolution of the hydroxyl camptothecin solid dispersion substances in dissolution media can reach more than 75%.
<P>PROBLEM TO BE SOLVED: To provide a technique capable of easily, safely, and uniformly peeling the skin at a low cost, without causing pain, and capable of uniformly applying a pharmaceutical or a cosmetic to a peeled part so as to impregnate the skin with the applied material, and to provide a device for the same.  <P>SOLUTION: A peeling pad holds polishing particles on its surface and is soft. A peeling brush is composed of many soft plastic fibers, wherein the polishing particles are adhered to a tip of each of the fibers. Thus, a surface of the skin is peeled by the peeling pad or the peeling brush. The peeling pad or the peeling brush is formed by making the pharmaceutical or the cosmetic absorbed in, adsorbed on, or filled into the polishing particles, a pad, hollow fibers, a container equipped with a brush composed of the hollow fibers, etc.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
INTRODUCTION: oral anticoagulant (DOAC) agents are becoming the anticoagulation strategy of choice for most clinical risks for which they are indicated. However, residual uncertainty remains regarding their use in preventing stroke in patients with low bodyweight [< 60 kg or body mass index (BMI) < 18 kg/m2]. We have carried out pooled systematic analyses of published studies to determine the efficacy and safety of these agents compared with warfarin in stroke prevention in patients with low bodyweight.
METHODS: We carried out a comprehensive search of electronic databases from inception to June 2023 for eligible studies reporting on the efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation who had low bodyweight. These include PubMed, EMBASE, the Cochrane Database of Systematic Reviews, the Science Citation Index, and the Database of Abstracts of Reviews of Effectiveness. Using the random effects model, derived pooled odd ratios (with their corresponding confidence intervals) of mortality outcomes in patient cohorts exposed to direct oral anticoagulants versus warfarin in patients with atrial fibrillation who had low bodyweight.
RESULTS: Nine studies (n = 159,514 patients) were included in our meta-analysis. DOAC analogs were associated with lower stroke recurrence compared with warfarin [odds ratio (OR) 0.66, 95% confidence interval (CI) 0.49-0.9]; however, there was no significant difference in the composite outcome (OR 0.81, 95% CI 0.59-1.09) and mortality (OR 0.82, 95% CI 0.48-1.41). Additionally, DOAC analogs showed a significant reduction in major bleeding events by 30% compared with warfarin (OR 0.70, 95% CI 0.62-0.80).
CONCLUSION: In this pooled meta-analytical synthesis of studies comprising both real-world and randomized controlled data, the use of DOAC analogs in patients with atrial fibrillation and low bodyweight (< 60 kg or BMI < 18 kg/m2) was associated with a significant reduction in risks of stroke and major bleeding compared with patient cohorts stabilized on warfarin-based therapy. There was uncertainty regarding the composite outcome and mortality point estimate between these two anticoagulation strategies. This finding helps to resolve the uncertainty associated with the use of DOACs in this cohort. Additionally, it suggests the need for confirmatory non-inferiority randomized controlled trials evaluating DOACs versus warfarin in this cohort of patients.
PURPOSE:An external preparation for the skin useful for remedying and preventing skin diseases such as humid tetter, acne, wound, etc., protecting the skin as a drug, quasi-drug, or cosmetic, containing 5-methylallantoin. CONSTITUTION:An external preparation for the skin containing 5-methylallantoin as an active ingredient. The external preparation for the skin has remedy promoting action on damaged parts such as wound, ulcer, burn, etc., astringent action, and covering action. It is useful for remedying erosion of the skin or mucosa, ulcer, and skin diseases such as humid tetter, etc., and used as a drug or quasi-drug having the above-mentioned medicinal effects. Since the active ingredient has no irritation to the skin, it may be blended with cosmetic, it prevents skin irritations of lips and chapped skin, is expected to have soft feeling in use, to make people undergo rejuvenation, etc. An amount of the active ingredient added is 0.01-20wt% based on the whole amount of pharmaceutical preparation, preferably 0.01-5wt% in the case of cosmetic, and 1-20wt% in the case of quasi-drug.